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The go-to cognitive enhancers of today are those that are widely available rather than
optimal for the user, including drugs typically prescribed for treatment of ADHD (e.g.,
methylphenidate) and sleep disturbances such as narcolepsy (modafinil). While highly
effective in their intended therapeutic role, performance gains in healthy populations are
modest at best and profoundly inconsistent across subgroups and individuals. We propose
a method for in silico screening of possible novel cognitive enhancers followed by high-
throughput in vivo and in vitro validation. The proposed method uses gene expression
data to evaluate the the collection of activated or suppressed signaling pathways in
tissues or neurons of the cognitively enhanced brain. An algorithm maps expression data
onto signaling pathways and quantifies their individual activation strength. The collective
pathways and their activation form what we term the signaling pathway cloud, a biological
fingerprint of cognitive enhancement (or any other condition of interest). Drugs can then
be screened and ranked based on their ability to minimize, mimic, or exaggerate pathway
activation or suppression within that cloud. Using this approach, one may predict the
efficacy of many drugs that may enhance various aspects of cognition before costly
preclinical studies and clinical trials are undertaken.
Keywords: nootropic, cognitive enhancement, personalized medicine, drug repositioning, oncofinder, in silico
medicine, signalome, signalome profiling
INTRODUCTION
The concept of cognitive enhancement is age-old, but despite
modern advances in our understanding of the cellular and
molecular bases of cognition, much remains unknown.
Development of new cognitive enhancers with increased
specificity, safety, and effectiveness must outpace increasing
demand, particularly as off-label and illicit use of current drugs
has become common in certain population subgroups (Maher,
2008) and as the aging segment of the population expands
with accompanying increases in rates of cognitive decline and
neurodegenerative disease (Wallace et al., 2011).
Cognition is complex and involves multiple domains, from
learning and memory to attention, and cognitive enhancers
can target one or more. At present, two of the most widely
cited cognitive enhancers are the dopaminergic stimulants
methylphenidate, prescribed for treatment of ADHD, and
modafinil, prescribed for treatment of sleep disorders, such as
narcolepsy. While both of these drugs can enhance memory
and attention in healthy individuals (Elliott et al., 1997),
their application as nootropics is secondary to their original,
therapeutic purpose, and effects are disagreed upon and modest
at best (Repantis et al., 2010).
A number of other potential nootropics have been
developed for the treatment of cognitive deficits in aging
and neurodegenerative or neuropsychiatric disease, from the
FDA approved acetylcholinesterase inhibitors (e.g., donepezil)
to those still under investigation: ampakines, nicotinic receptor
agonists, glutamate receptor agonists, glycine inhibitors, and
PDE inhibitors (for review, Wallace et al., 2011; Pieramico
et al., 2014). Drugs that may play a more modulatory role
target histamine, serotonin, glucocorticoid, and neuropeptide
receptors and epigenetic mechanisms (Roesler and Schröder,
2011; Wallace et al., 2011). Many other drugs positioned as
nootropic agents like piracetam and piracetam-like compounds
are well-tolerated, but their effects and mechanisms of action are
poorly understood and widely debated (Gouliaev and Senning,
1994; Gualtieri et al., 2002). While some nootropics have made
it to clinical trial, others still await or have been withdrawn, and
each has various drawbacks or only modest effects that are disease
specific.
Development of novel nootropics is hampered by research,
validation and regulatory challenges. The very definition of
cognitive enhancement is difficult to pin down (Lynch et al.,
2014). The road from lab to FDA approval is difficult, long, and
costly. Pharmacological enhancement of healthy populations
is fraught with ethical and philosophical pushback (Maslen
et al., 2014). Enhancement in aging and neurodegenerative
disease is less controversial, but perhaps more complex
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(Pieramico et al., 2014). Moreover, therapeutic effects often
contradict those in healthy populations (Kimberg et al., 1997;
Belmonte and Yurgelun-Todd, 2003; Beglinger et al., 2005; Gibbs
and D’Esposito, 2005, 2006; Randall et al., 2005; Frank and
O’Reilly, 2006; Finke et al., 2010; Esposito et al., 2013). The
U-shaped curve effect, wherein treatment effects benefit low-
baseline performers but impair high-performers, is a problem
with at least the dopaminergic drugs (Gibbs and D’Esposito,
2006; Finke et al., 2010; Esposito et al., 2013). Even drugs
FDA-approved for therapeutic use have issues with side effects,
trade-offs (one process is enhanced while another is impaired),
loss of authenticity (one’s true “self ”), and large individual
differences (Maslen et al., 2014). Long term effects are typically
unknown. Finally, and most importantly, there is still much to
be learned about the cellular and molecular basis for the various
aspects of cognition.
For the field of neuroenhancement to advance, the
benefit-to-risk ratio of pharmacological treatment must
improve. This will require (a) a better understanding of the
neurobiological basis of cognition; and (b) drugs with higher
specificity, greater effectiveness, and fewer side effects. To
this end we propose an expedited path to understanding the
molecular basis of cognition and to subsequent drug discovery
via a combination of advanced gene expression analysis,
signaling pathway analysis, and in silico screening of potential
nootropics. In our approach, current drugs will simply be the
launching pad on the quest to find new, better performing
nootropics.
SIGNALING PATHWAY ACTIVATION PROFILES AS DRUG
TARGETS FOR PREDICTING NOOTROPIC EFFECTS IN SILICO
Enhancing cognition is a challenge as it consists of various
processes each influenced by many factors and each with a
distinct neurobiological framework. While single-gene studies
have been an effective first step in identifying individual elements
necessary for learning and memory to occur (Lee and Silva,
2009), in moving forward, integration of many other factors
and influences, including the relatively few signaling pathways
involved, may be more beneficial than investigating each of many
potential individual network elements.
Intracellular signaling pathways show promise for complex
trait analysis. At the cellular level, any two physiological states can
be distinguished by changes in a set of signaling pathways, each
individually activated or repressed to some extent. This collection
of disturbed pathways, termed the signaling pathway cloud, is
a powerful and unique biological fingerprint (Zhavoronkov and
Cantor, 2011; Makarev et al., 2014; Aliper et al., 2015).
Until recently, signaling pathway analysis was impeded by
the inability to quantify individual signaling pathway activation
strength (PAS), owing to the complexity of protein interactions
within signaling pathways and lack of experimental data to
determine the importance factor for each member of a given
pathway. This problem was addressed, however, with the
development of Oncofinder1, a biomathematical method that
simplifies calculation of PAS and signaling pathway cloud
1www.oncofinder.com
disturbance (SPCD), as detailed below (Buzdin et al., 2014b).
With the ability to calculate PAS, one can quantitatively
characterize a biological condition by its associated signaling
activation profile.
PAS analysis involves (1) mapping relevant pathways
from the gene expression profiles for a given condition;
(2) calculating individual PAS values; (3) constructing the
signaling pathway cloud (net activated and repressed pathways);
(4) high throughput in silico screening to predict and rate drugs
that target these pathways, depending on the application; and
(5) in vitro and in vivo validation.
The pair of conditions to be compared in signaling pathway
cloud analysis is flexible. In the past, we have compared tumor
biopsies to healthy tissue, revealing signaling pathway biomarkers
that outperform those of single genes (Kuzmin et al., 2010;
Mityaev et al., 2010; Zabolotneva et al., 2012a,b), and tissue from
old vs. young patients, illustrating how this method may be useful
for the screening of potential geroprotectors (Zhavoronkov and
Cantor, 2011). Other applications include drug discovery and
drug repurposing, as well as applications in manipulating cell
differentiation.
Here, we suggest that these methods could also be applied to
cognitive enhancement, first by defining what aspect of cognition
is to be targeted, then by mapping signaling pathways altered in
transcription profiles of the “enhanced brain” vs. control (e.g., in
mouse models showing performance gains in the target cognitive
domain, whether via genetic manipulation, selective breeding or
inbreeding, or treatment with current nootropics) and finally by
calculating disturbance of the associated signaling pathway cloud
(Figure 1).
High throughput screening for drugs that activate or repress
key pathways could then uncover drugs that replicate cloud
disturbance in “enhanced” models and thus mimic or exaggerate
the effects of the current drugs or genetic manipulations. These
drugs could then be ranked and prioritized for validation of
cognitive effects in vivo or in vitro.
These methods can be used for general screening of cognitive
enhancers at present but in the future may also be used to
develop personalized cognitive enhancement plans for individual
patients.
The idea of using differential gene expression patterns for
drug discovery is not new. The broad variability of as well as
the error rates introduced by the microarray and next generation
sequencing (NGS) equipment led to many early failures, impeded
progress and diminished the potential of this approach. However,
recent algorithmic solutions reducing complexity and smoothing
variability of the gene expression mapped onto signaling pathways
allow us to minimize errors and perform cross-platform analysis
(Buzdin et al., 2014b). These solutions allow us to tap into legacy
databases and compare hundreds of thousands of data sets in
microarray and NGS repositories as well as utilize the drug effects
on gene expression published in publically available databases.
STEP 1: IDENTIFYING THE PAIR OF CONDITIONS
Enhanced cognition can refer to augmented function across
one or several domains and can be demonstrated in a number
of highly specific paradigms or tests, thus one must first
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FIGURE 1 | Using differential signaling pathway activation profiles between cell/tissue culture or mice treated and untreated with known cognitive
modulators or genetic models of cognitive enhancement to screen for potential nootropic compounds.
specify the goals of enhancement and choose models/tissues that
demonstrate enhancement in that respect.
Ethical considerations preclude the use of human studies
for this application, thus animal models would be required.
Fortunately, a number of animal models are highly useful in
investigating mechanisms of cognition (Roesler and Schröder,
2011). Specific aspects of attention, learning, and memory can
be reliably measured in a wide variety of behavioral paradigms.
Many of these have been developed for use in mice, but rats,
monkeys, zebrafish, and drosophila are also potential models. For
the current approach, mouse models are promising, and there are
several different options within this species for comparison of the
“enhanced” vs. “non-enhanced” brain.
MUTANT vs. WILD TYPE
Mice are a classic model for learning and memory and a
number of models involve mutations that induce cognitive
enhancement, including knockout and transgenic mutations (Lee
and Silva, 2009). These model systems have revealed many genes
involved in learning and memory. Hypothetically, the human
orthologs of these genes would also be involved in cognition.
Mutations that enhance cognition are varied in mechanism, and
include enhancing excitation, dampening inhibition, regulating
gene expression, regulating translation, epigenetics, microRNA
biogenesis, and extracellular molecules (Lee and Silva, 2009).
Generally speaking, mutations that increase the activity of cAMP
response element-binding protein (CREB), a basic leucine zipper
transcription factor, enhance long-term potentiation (LTP) and
both long and short term memory, while those that downregulate
CREB activity impair LTP and memory (Lee and Silva, 2009;
Suzuki et al., 2011; Kida and Serita, 2014). In their 2009 review,
Lee and Silva reported that 26 of the 29 mouse models reviewed
showed enhanced LTP. In several cases, LTP was enhanced, but
cognition was either not improved or was actually impaired; thus,
other signaling pathways and cellular processes are involved (Lee
and Silva, 2009), underscoring the potential role for signaling
pathway analysis in elucidating global effects on these mice and
thereby enabling pharmacological replication.
STRAIN vs. STRAIN
An alternative to single gene mutation models is selective breeding
or inbreeding to exploit “natural” genetic variation among mouse
strains in cognitive performance. Strains or groups of strains
that perform high on paradigms of learning and memory can
be compared to other low-performing strains within a genetic
reference panel. The BXD strains are a good example (Williams
et al., 2003). This panel of recombinant inbred strains has
been extensively phenotyped for behaviors related to learning
and memory and drug treatment effects as well as profiled for
basal gene expression, and the data are publicly available for
rapid statistical analysis on genenetwork.org (Wang et al., 2003).
In minutes, known phenotypic differences can be correlated
to known gene expression levels (and thus signaling pathway
activation), without the unwanted or exaggerated effects of
knockout or transgenic manipulation.
DRUG-TREATED vs. DRUG-NAïVE
A third alternative for comparisons in the analysis would be
in vivo or in vitro expression in organisms, tissues, or cells that
have been pharmacologically treated with current nootropics
vs. control. The effect of nootropics on gene expression in the
brain can be large; in the case of methylphenidate treatment,
over 2000 genes have been shown to be differentially expressed
in the caudate putamen of mice (Adriani et al., 2006a,b). This
comparison would enable screening of new nootropics that mimic
current nootropics, but that are more effective, more or less
specific in targeted cognitive domains, and/or have fewer side
effects.
STEP 2: IDENTIFYING TARGET SIGNALING PATHWAYS
Once a specific comparison is decided upon, a predicted set
of relevant pathways can be assembled from the literature
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or mapped from gene expression data. Here, we reviewed
the literature for mouse models of cognitive enhancement,
in which overexpression, knockout, loss-of-function mutation,
deletion, or RNA interference of a particular gene led to
significant gains in cognitive performance as measured in
at least one behavioral paradigm for measuring learning
and/or memory. In 2009, Lee and Silva reviewed these
models and compiled list of target genes and effects of
mutation. We reduced this list to only 40 genes, for which
human orthologs exist. Gene set enrichment analyses of
these listed entries against Insilico Cloud Intelligence signaling
pathway database (Buzdin et al., 2014a) were performed
using Fisher’s exact test and the most enriched pathways are
shown in Table 1. Results revealed several overrepresented
signaling pathways, including IP3, IGF1R, and cAMP molecular
signalization, potentially important for learning and memory
in humans. Key activators/repressors of these pathways can
therefore be used in further experimental assays together
with the mathematical apparatus we provide in the following
section.
Importantly, many of the genes and pathways identified during
in silico screening of nootropics are also implicated in aging and
longevity (Zhavoronkov and Cantor, 2011; Moskalev et al., 2014)
thus suggesting that geroprotector drugs may act as nootropic
agents and vice versa.
STEP 3: CALCULATING SIGNALING PATHWAY CLOUD
DISTURBANCE
The work we propose involves calculating signaling activation
and methods are based on our prior work with cell signaling
pathways (Kiyatkin et al., 2006; Kuzmina and Borisov, 2011;
Borisov et al., 2014). In the past, calculation of signaling
pathway activation has been avoided because of the lack of
experimental data measuring the correlation between expression
and activation at the protein level. In our observation, most signal
transduction proteins are far from saturation even at the peak
concentrations of the activated form, in comparison with total
protein abundance. From this, we suggest all activator/repressor
gene products/proteins have equal importance for pathway
activation/downregulation. We then arrive at the following
assessment: function for overall signal pathway cloud disturbance
outcome (SPCD) is proportional to the following estimator
function:
SPCD =
N∏
i=1
[AGEL]i
M∏
j=1
[RGEL]j
Here, the multiplication is performed over all possible activator
and repressor proteins in the pathway, and [AGEL]i and [RGEL]j
are gene expression levels of an activator i and repressor j,
respectively. To obtain an additive (not multiplicative) value,
one can simply switch from using absolute values of expression
levels to their logarithms, arriving at the PAS value for each
pathway
PASp =
∑
n
ARRnp · BTIFn · lg(ECRn)
In the case of cognitive enhancement, to obtain the values of
enhanced-to-control ratio (ECR), one divides the expression
levels for a gene n in the sample taken for the enhanced
group by the same average value for the normalized
control group. The discrete value of activator/repressor role
(ARR) is the relative strength of the target activation or
repression.
The information about the activator/repressor role of a
particular gene product/protein may be obtained from the
analysis of open-access or customized pathway databases and
from the literature. The Boolean flag of BTIF (beyond tolerance
interval flag) equals to zero when the ECR value lies within
the tolerance limit, and to one when otherwise. We determined
that the ECR lies beyond the tolerance limit if it satisfies
simultaneously the two criteria. First, it should be either higher
than 3/2 or lower than 2/3 of the corresponding gene expression
level in normal group of samples, and, second, the expression level
of a gene should differ by more than two standard deviations from
the average expression level for the same gene in a control group
of samples.
LIMITATIONS OF DIFFERENTIAL SIGNALING PATHWAY
ANALYSIS-BASED DRUG SCREENING METHODS
Acquiring gene expression data from the various regions of
human brain during excitation is difficult and human data
Table 1 | Signaling pathways associated with cognitive enhancement in animal models.
Pathway name Overlap with gene list (%) Odds ratio p-value
IP3 pathway (gene expression) 25.9 0.346 1.53E − 08
IGF1R pathway (cell survival) 17.9 0.215 2.39E − 07
cAMP pathway (axonal growth) 20.8 0.245 6.88E − 06
IGF1R main pathway 6.6 0.073 2.09E − 05
IP3 main pathway 5.2 0.058 0.000142525
IL-2 main pathway 4.4 0.044 0.002495586
Wnt main pathway 2.8 0.029 0.028947377
GPCR main pathway 2.5 0.025 0.033190669
cAMP main pathway 2.1 0.021 0.034326773
Gene set enrichment analyses of the genes implicated in cognitive performance against Insilico Cloud Intelligence signaling pathway database performed using
Fisher’s exact test and the most enriched pathways.
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would have to be obtained from post mortem tissues or cultured
cells or tissues. Gene expression data from mouse brain is
easier to obtain, but further studies are required to evaluate the
correlations between signaling pathway activation profiles in mice
and humans. Tissue selection is also important, gene expression
in one region or cell type may or may not be representative of
other areas of the brain and may not capture all effects of a
given condition. Also, gene expression alone may not provide the
complete picture of the state of the tissue, and while the pathway
activation analysis approach may be used to analyze differences
in genomic DNA (Spirin et al., 2014) there may be epigenetic
regulation of cognitive states that may require other analytical
methods to be performed. Aside from tissue selection, the
complexity of cognition presents other challenge. The proposed
approach evaluates the various drugs and drug combinations
that mimic or enhance the effects of already known nootropics
or genetic manipulations; however, no current nootropic agents
optimally enhance specific aspects of cognitive function without
side effects, and even genetic models of cognitive enhancement
can produce unintended impairments (Lee and Silva, 2009).
In this paper, we have referred to the “enhanced” brain vs.
control in describing the comparisons one would use to perform
signaling pathway analysis. However, “enhanced” is a simplified,
general term that does not specify effects on the various cognitive
domains, and defining enhancement remains an important issue
in developing new nootropics (Lynch et al., 2014).
CONCLUSION
Cognitive enhancement is in demand, whether in healthy
populations or those with cognitive deficits, but current
pharmacological enhancers offer only modest benefits. Testing
of new cognitive enhancers is costly and time consuming. Even
predicting the nootropic candidates out of the hundreds of
thousands of drugs and drug combinations remains a major
challenge. A screening process that would predict the efficacy
of novel cognitive enhancers that may outperform current
options would save time and money, both of which are limiting
as the aging segment of the population explodes over the
upcoming decades, with increasing rates of cognitive decline
and neurodegenerative disease. Here we propose a method for
in silico screening and ranking of drugs and other factors that
act on signaling pathways involved in cognition. Predicting their
efficacy would involve calculating their potential to maximize
the difference in signaling pathway activation between cells or
tissues of cognitively enhanced animal models, including mutant
“smart” vs. wild type mice, high-performing vs. low-performing
strains of mice, or drug-treated vs. drug naïve mice. This would
be followed by in vitro and in vivo validation leading to a short list
of promising components.
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